-
Sales down as focus shifts to weight management
It’s been a little more than a year since GlaxoSmithKline Consumer Healthcare announced the return of Alli (orlistat 60 mg capsules) to most stores in the United States and Puerto Rico. Today, the over-the-counter diet aid has reclaimed much of its lost dollar base and its No. 2 spot on the list of best-selling diet aids across total U.S. multi-outlets with $30.8 million in sales for the 52 weeks ended April 17.
-
FDA approves Jentadueto XR from Boehringer Ingelheim, Lilly
SILVER SPRING, Md. — The Food and Drug Administration has approved Boehringer Ingelheim and Eli Lilly and Co.’s Jentadueto XR (linagliptin and metformin HCl) tablets, the companies announced Tuesday.The new drug is indicated as a once-daily adjunctive treatment for Type 2 diabetes and works by increasing hormones that stimulate insulin production in the pancreas and that stimulate the liver to produce less glucose.